Zobrazeno 1 - 10
of 24
pro vyhledávání: '"L. M. Blatt"'
Publikováno v:
American Journal of Gastroenterology. 94:1605-1612
Chronic infection with hepatitis C may lead to the development of cirrhosis, liver failure, and hepatocellular carcinoma. However, not all patients progress to these endpoints. Ideally, clinicians could improve their capability of stratifying the ris
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03924df78b695006938542d1f3e64b0
https://doi.org/10.1111/j.1572-0241.1999.01151.x
https://doi.org/10.1111/j.1572-0241.1999.01151.x
Publikováno v:
Journal of Viral Hepatitis. 5:323-331
Nineteen patients with chronic hepatitis C who were virological non-responders (seven responder/relapse and 12 no response) to an initial 24-week course of interferon-alpha 2b (IFN-alpha 2b) at a dose of 3 million units (MU) thrice weekly were retrea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dad378581d6d2be1897c9056e88271e
https://doi.org/10.1046/j.1365-2893.1998.00120.x
https://doi.org/10.1046/j.1365-2893.1998.00120.x
Publikováno v:
American Journal of Gastroenterology. 93:601-605
Our aim was to analyze the outcomes and the patterns of response to interferon treatment in patients with chronic hepatitis C using serum HCV RNA as the primary endpoint of therapy.Seventy anti-HCV-positive patients were treated with 3 million U of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e89d02328407ade7f13ed0412c73421a
https://doi.org/10.1111/j.1572-0241.1998.172_b.x
https://doi.org/10.1111/j.1572-0241.1998.172_b.x
Autor:
L M Blatt, M Klein, Myron J. Tong, F B Hollinger, M Black, H White, R T Foust, J Lubina, D M Jensen, William M. Lee, H Fromm, E J Hathcote, E B Keeffe, E L Krawitt, K R Reddy, P J Pockros, J C Hoefs
Publikováno v:
Hepatology. 26:747-754
This multicenter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C infection compared treatment with consensus interferon (CIFN), a non-natural recombinant type-1 interferon, with a standard regimen of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fda4821f7197ae02fb5ee1e58c6aea71
https://doi.org/10.1002/hep.510260330
https://doi.org/10.1002/hep.510260330
Autor:
J A, Sandberg, V P, Parker, K S, Blanchard, D, Sweedler, J A, Powell, A, Kachensky, L, Bellon, N, Usman, T, Rossing, E, Borden, L M, Blatt
Publikováno v:
Journal of clinical pharmacology. 40(12 Pt 2)
The pharmacokinetics and tolerability of a chemically stabilized synthetic ribozyme (ANGIOZYME) targeting the Flt-1 VEGF receptor mRNA were evaluated in healthy volunteers. In a placebo-controlled, single-dose escalation study, ribozyme was administe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f148ebb41b319b48daa8e86db76eab78
https://pubmed.ncbi.nlm.nih.gov/11185667
https://pubmed.ncbi.nlm.nih.gov/11185667
Publikováno v:
Journal of gastroenterology and hepatology. 15(8)
Chronic hepatitis C is a slowly progressing inflammatory disease of the liver that can lead to cirrhosis and its complications. Assessment of liver damage in hepatitis C has been primarily via histological evaluation. Liver biopsy, while useful in de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::920cbb26f87615c4ced9950fe3fa1c81
https://pubmed.ncbi.nlm.nih.gov/11022820
https://pubmed.ncbi.nlm.nih.gov/11022820
Publikováno v:
Journal of medical virology. 57(4)
The ability to predict accurately a sustained response during therapy in patients with hepatitis C virus (HCV) infection is unavailable. The aim of this study was to differentiate, during therapy, patients who would relapse from those with a sustaine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0c5ff6074f24f90d2b2a9a420a4dc1a1
https://pubmed.ncbi.nlm.nih.gov/10089045
https://pubmed.ncbi.nlm.nih.gov/10089045
Publikováno v:
Hepatology (Baltimore, Md.). 26(6)
Patients with chronic hepatitis C (n = 103) were treated for 24 weeks with interferon alfa 2b and followed up for 24 weeks after cessation of therapy (week 48). When hepatitis C virus (HCV) RNA at week 48 was used to assess interferon response, 15 (1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffd448180a05a25d2ff2b848c84a0c16
https://pubmed.ncbi.nlm.nih.gov/9398010
https://pubmed.ncbi.nlm.nih.gov/9398010
Autor:
M J, Tong, K R, Reddy, W M, Lee, P J, Pockros, J C, Hoefs, E B, Keeffe, F B, Hollinger, E J, Hathcote, H, White, R T, Foust, D M, Jensen, E L, Krawitt, H, Fromm, M, Black, L M, Blatt, M, Klein, J, Lubina
Publikováno v:
Hepatology (Baltimore, Md.). 26(3)
This multicenter, randomized, controlled, double-blind, phase III study in 704 patients with chronic hepatitis C infection compared treatment with consensus interferon (CIFN), a non-natural recombinant type-1 interferon, with a standard regimen of re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8ac7a1c8916bed3e25c36608bc1904b6
https://pubmed.ncbi.nlm.nih.gov/9303508
https://pubmed.ncbi.nlm.nih.gov/9303508
Publikováno v:
The Journal of urology. 156(5)
Although treatment with interferon-alpha (IFN alpha) results in tumor regression in a subset (20%) of patients with renal cell carcinoma, the underlying mechanisms for the resistance of renal cancer (RC) cells to IFN alpha is unknown.We examined 5 RC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a06beaadc66efed740ed20080bc92f3
https://pubmed.ncbi.nlm.nih.gov/8863634
https://pubmed.ncbi.nlm.nih.gov/8863634